Weight Management & Fat Loss

Overview

Weight-management peptide research is the most clinically validated category in the catalog. Incretin-class agents -- GLP-1 receptor agonists (semaglutide), dual GLP-1/GIP agonists (tirzepatide), triple GLP-1/GIP/glucagon agonists (retatrutide), and dual GLP-1/glucagon agonists (survodutide) -- have transformed obesity therapeutics with consistent double-digit percentage weight reductions in large randomized trials. Adjacent compounds include the amylin analog cagrilintide (and its fixed combination CagriSema with semaglutide), the GHRH analog tesamorelin (FDA-approved for HIV-associated visceral adiposity), and the GH-fragment AOD9604 (which failed its Phase 2b obesity endpoint and is now used as a cosmetic-style fat-loss compound with weak evidence). Research distinguishes appetite-driven weight loss from compositional shifts (fat versus lean) and from cardiometabolic outcome improvement.